IVEVF Inventiva S.A.
Price Chart
Executive Summary
Inventiva S.A. filed a 6-K attaching a Subscription Agreement with funds managed by BlackRock and Claret Capital Partners for a comprehensive debt restructuring deal totaling €130M (expandable to €150M) and a Master Agreement with the EIB to repurchase EIB warrants and prepay the EIB loan. The transaction includes a €120M ADS offering closed yesterday, paving the way to replace existing EIB debt with new secured financing from BlackRock/Claret.
Actionable Insight
The refinancing deal extends Inventiva's cash runway well into 2028, eliminates the dilutive overhang from EIB warrants, and provides a clear pathway to fund the NATiV3 trial through top-line results. The forced conversion mechanism at 175% and the conversion price premium reflect moderate dilution risk but strong debt restructuring terms. Monitor for NATiV3 trial data, which triggers potential Tranche C drawdown and equity-linked pricing reset. The 94% bull analyst consensus already prices in some of this positive capital structure cleanup.
Key Facts
- Inventiva entered a Subscription Agreement with BlackRock and Claret Capital for €130M (expandable to €150M) in amortized bonds and convertible bonds (OCAs).
- The deal includes a €35M OCA tranche (9.9% interest) and €40M Tranche B amortized bonds (9.9% cash + 2.1% PIK), plus an optional €55M Tranche C and €20M non-committed tranche conditional on NATiV3 results.
- A simultaneous $120M ADS offering at $4.40/ADS closed on June 2, 2026, satisfying the condition to raise at least €90M in equity.
- The company entered a Master Agreement with the EIB to prepay the entire €50M EIB loan and repurchase 2,966,023 EIB warrants for €50M, eliminating the EIB's ant-dilution protections and restructuring remaining warrants.
- The OCA conversion price is set at a 40% premium to a 30-day VWAP floor, with a forced conversion threshold at 175% of the conversion price.
- Post-closing, the company must maintain a minimum €30M cash balance, and upon NATiV3 success, an additional €75M cash balance requirement applies.
Financial Impact
€130M new debt facility replacing €50M EIB loan, plus $120M equity raise (€112.8M net) — total new cash estimated at ~€230M.
Risk Factors
- Conversion of €35M OCAs into shares at a 40% premium to VWAP could still result in significant dilution if the stock price remains depressed.
- Failure of the NATiV3 trial (Primary Composite Endpoint) triggers a Termination Event with mandatory prepayment and potential acceleration of all debt.
- The company posted a $354M net loss and declining revenue in 2025 — the new debt at 9.9%+ interest adds heavy fixed cost for a pre-commercial firm.
- Tranche C and the €20M non-committed tranche only become available upon NATiV3 success and additional T3 warrant exercise — no guarantee of execution.
Market Snapshot
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-069638 |
| Document: tm2616655d1_ex1-2.htm | 0001104659-26-069638 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
3d ago
|
6-K
| $5.33 awaiting T+1 | awaiting T+1 | — | $5.33 (−0.00%) |
|
Jun 3, 2026
9d ago
|
6-K
| $5.33 $5.33 | · 0.00% | ▼ −0.40% | $5.33 (−0.00%) |
|
Jun 3, 2026
10d ago
|
6-K
| $5.33 $5.33 | · 0.00% | ▼ −0.40% | $5.33 (−0.00%) |
|
May 26, 2026
17d ago
|
6-K
| $5.33 $5.33 | · 0.00% | ▼ −0.55% | $5.33 (−0.00%) |
|
May 22, 2026
21d ago
|
6-K
| $5.33 $5.33 | · 0.00% | ▲ +0.01% | $5.33 (+0.00%) |
|
Apr 8, 2026
9w ago
|
20-F
| $5.50 $5.50 | · 0.00% | ▲ +0.57% | $5.33 (+3.09%) |
|
Mar 30, 2026
10w ago
|
6-K
| $5.50 $5.50 | · 0.00% | ▼ −0.75% | $5.33 (−3.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access